AbCellera Biologics (ABCL, Financial) saw its price target significantly increased by analyst Scott Schoenhaus of KeyBanc. On July 14, 2025, KeyBanc raised the price target for ABCL from $5.00 to $10.00 USD, representing a 100% increase.
The rating for AbCellera Biologics (ABCL, Financial) remains unchanged at "Overweight," indicating ongoing confidence from the analysts at KeyBanc.
Investors in AbCellera Biologics (ABCL, Financial) may view this adjustment as a positive signal, reflecting expectations of growth and potential upside in the company’s financial outlook according to KeyBanc’s analysis.
Wall Street Analysts Forecast
Based on the one-year price targets offered by 7 analysts, the average target price for AbCellera Biologics Inc (ABCL, Financial) is $9.14 with a high estimate of $17.00 and a low estimate of $5.00. The average target implies an upside of 128.00% from the current price of $4.01. More detailed estimate data can be found on the AbCellera Biologics Inc (ABCL) Forecast page.
Based on the consensus recommendation from 9 brokerage firms, AbCellera Biologics Inc's (ABCL, Financial) average brokerage recommendation is currently 1.9, indicating "Outperform" status. The rating scale ranges from 1 to 5, where 1 signifies Strong Buy, and 5 denotes Sell.
Based on GuruFocus estimates, the estimated GF Value for AbCellera Biologics Inc (ABCL, Financial) in one year is $1.61, suggesting a downside of 59.85% from the current price of $4.01. GF Value is GuruFocus' estimate of the fair value that the stock should be traded at. It is calculated based on the historical multiples the stock has traded at previously, as well as past business growth and the future estimates of the business' performance. More detailed data can be found on the AbCellera Biologics Inc (ABCL) Summary page.
